Difference In Primary Patency Rates Research Articles

Comparative efficacy of five balloons for treating autogenous arteriovenous fistula stenosis: a Bayesian network meta-analysis.

Arteriovenous fistula (AVF) was the lifeline of patients with maintenance hemodialysis (MHD). However, stenosis of AVF may limit its use. Currently, AVF stenosis is commonly treated with balloon angioplasty. Meanwhile, several balloons were available. Therefore, this study aimed to explore the effectiveness of angioplasty with five different balloons in patients with AVF stenosis. A network meta-analysis (NMA) was performed to synthesize direct and indirect evidence. We carried out a comprehensive literature search in PubMed, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and ClinicalTrials.gov databases from database inception to January 31, 2021. The main outcomes were primary patency rates of AVF after 3, 6, 9, and 12 months. The NMA was performed using Stata 15 (network and mvmeta commands) and GeMTC software. Twenty randomized controlled trials (RCTs) involving 2,607 participants were included. Direct meta-analyses revealed no significant difference in primary patency rates between different balloons after 3, 6 and 9 months. However, NMA demonstrated that the effectiveness of plain balloon angioplasty (PBA) was inferior to that of the drug-coated balloon (DCB) after 3 and 9 months. Moreover, the results suggested that the high-pressure balloon (HPB) was inferior to DCB after 9 months. Thereafter, the analysis of the surface under the cumulative ranking curve (SUCRA) revealed that DCB was ranked as the first effective treatment after 3 months. The drug-eluting balloon (DEB) was the most effective treatment after 6, 9, and 12 months. The analyses revealed no significant publication bias. DEB may be the most effective treatment of AVF stenosis, followed by DCB. However, prospective studies involving large sample sizes of clinical trials and a direct comparison between DEB and DCB are required to clarify the individual value of different treatment options.

Comparison of Interwoven Nitinol and Drug-Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.

Interwoven nitinol stents (INS) and drug-eluting stents (DES) were designed to improve the mid- and long-term results of femoropopliteal (F-P) angioplasty. The aim of this study was to systematically compare these stents. Between 2015 and 2017, 62 patients with symptomatic peripheral artery disease of the F-P segment treated by INS or DES were identified from a prospectively maintained institutional database. The primary outcome measure was one-year primary patency; secondary outcomes were in-stent restenosis (ISR), stent occlusion, target lesion revascularization (TLR) and mortality. The mean follow-up was 26.9 ± 11.2 months. No statistically significant difference in primary patency at one year was observed (88.6% vs. 88.9%). Throughout follow-up, overall rates of ISR (5.7% vs. 11.1%, p = 0.645), stent occlusion (25.7% vs. 7.4%, p = 0.094) and TLR (25.7% vs. 18.5%, p = 0.505) were statistically equivalent between the groups. Mortality reached 14.3% in the INS group and 3.7% in the DES group, but this difference was not statistically significant (p=0.196). Multivariable analysis revealed significant correlations between ISR and stent occlusions; popliteal lesion localization (p = 0.016) and poor below the knee vessel outflow (p < 0.001). In the short- and mid-term, the use of an INS or DES in the F-P arterial segment did not result in a difference in primary patency rate, stent occlusion, restenosis, re-intervention or mortality. The overall data do not provide any evidence to favor one stent over the other.

Endovascular Treatment of Malignant Superior Vena Cava Syndrome through Upper-Limb Access: A Comparison between Venous-Dedicated and Conventional Stents

PurposeTo retrospectively evaluate the technical and clinical outcomes of superior vena cava (SVC) stent placement through upper-limb venous access in malignant SVC syndrome (SVCS) and compare the efficacy of different nitinol stent types. Materials and MethodsBetween 2006 and 2018, 156 patients (132 male; mean age, 62 y; age range, 33–81 y) underwent SVC stent placement for malignant obstructions through upper-limb venous access with 1 of 3 types of nitinol stent: 1 venous-dedicated (Sinus-XL stent) and 2 non–venous-dedicated (E-Luminexx Vascular Stent and Protégé GPS). Cases of common femoral vein access or non-nitinol stents were excluded from further analysis. The mean duration of follow-up was 8 mo. ResultsTechnical success was achieved in 99.3% of cases. One patient died during the procedure as a result of cardiac tamponade. Balloon predilation was performed in 10 patients and postdilation in 126. Mean procedural time was 34.4 min (range, 18–80 min). Overall survival rates were 92.3%, 57.3%, and 26.8%, and overall primary patency rates were 94.5%, 84.8% and 79.6%, at 1, 6, and 12 mo, respectively. There were no statistically significant differences in primary patency rates between venous- and non–venous-dedicated stents or among different Stanford SVCS grading groups (P > .05). ConclusionsSVC stent placement through an upper-limb approach is a safe, fast, and effective technique. There is no evident benefit of venous-dedicated vs non–venous-dedicated stents in the treatment of malignant SVCS.

Differences in Post-Cholecystectomy Bile Duct Injury Care: A Comparative Analysis of 2 Different Health-Care Public Institutions in a Low- and Middle-Income Country: Southeast Mexico

Background: Mexican health system structure allows us to study the differences in bile duct injury (BDI) management. The study aimed to assess the differences in patients with complex BDI in 2 different public sector institutions using a new proposed standard terminology. Methods: Retrospective review (2008–2019) in 2 public institutions (IMSS/SESVER). Bismuth-Strasberg E injuries with hepaticojejunostomy were included. Data are presented in a tabular reporting system. The outcomes were percent of patients attaining primary patency, loss of primary patency, and actuarial primary patency rate. Results: Seventy-eight patients (IMSS: n = 37; SESVER: n = 41) without differences in demographic and preoperative assessment were studied. BDI occurred mostly in outside hospitals. Open cholecystectomy was the most common index operation in SESVER (73%, p = 0.02). IMSS had more surgeries (p = 0.007) and repair attempts (p = 0.06) prior to referral. Magnetic resonance cholangiopancreatography was more commonly used in IMSS patients. Biliary stents (45%) and cholangitis (29%) were more common in IMSS (p < 0.05). IMSS patients had longer follow-up than SESVER (p < 0.05). No differences in primary patency rates (IMSS: 89%, SESVER: 97%) and actuarial patency rates were noted. Discussion: Despite differences in referral, preoperative, and operative events, good BDI repair outcomes can be achieved. Longer follow-up is needed to monitor these outcomes.

Impact of PTFE-covered stent position and extension on TIPS patency.

The objectives of this study were to determine the effects of expanded polytetrafluoroethylene (PTFE)-covered stent location and TIPS extension on primary patency. This retrospective cohort study examined patients with PTFE-covered TIPS creation between 07/2002 and 06/2016. Clinical information and patency outcomes at 24months were extracted. At TIPS creation, extension was performed at the discretion of the operator. Kaplan-Meier curves of primary patency were generated with conditional variables of HVO-HCJ distance, extension status, and covered versus uncovered extensions. Additional logistic regression analyses of distances were performed. Of 393 patients, 115 patients (29%) underwent stent extension, 79 (20% of total cohort) of which were at the HVO end alone. Primary patency for all TIPS was 75%, 68%, and 54% at 3, 6, and 12months. The data endpoint were transplant or death in 92 (23%) and 116 (30%). Kaplan-Meier curves showed no statistically significant difference between the variables and primary patency at 12 and 24months: distance up to versus greater than 10mm (p = 0.32, 0.81); extension versus no extension (p = 0.83, 0.85); uncovered versus covered extensions (p = 0.58, 0.70). Logistic regression analyses showed a trend toward statistical significance. In the setting of PTFE-covered TIPS creation, extended TIPSs and unextended well-positioned TIPSs have no difference in primary patency rates. Stent position and extension length may have an effect on primary patency, but were likely obscured by "user recognition" effects.

Endovascular treatment of different types of iliac occlusions—Results from an observational study

ObjectiveThe aim of this study was to evaluate the results of endovascular therapy on the treatment of different types of iliac occlusions.Materials and methodsA bi-center prospective, non-randomized study was conducted on 100 patients (mean age 59.14 ± 8.53; 64 men) who underwent endovascular treatment of iliac occlusive disease between January 2013 and November 2017. We evaluated baseline data, procedure, and follow-up results for the entire group, and according to Trans-Atlantic Inter-Society Consensus (TASC II) classification. The majority of patients (60%) were treated for severe claudication; 56 (56%) patients had TASC B occlusions, 28 patients TASC C, and 16 patients TASC D.ResultsThe mean length of the occluded segments was 61.41 ± 35.15 mm. Procedural complications developed in 6 patients (6%). Mean ankle-brachial pressure index increased from 0.40 ± 0.12 preoperatively to 0.82 ± 0.16 postoperatively. The mean follow-up was 33.18 ± 15.03 months. After 1 and 5 years, the primary patency rates were 98% and 75.1%, and the secondary patency rate was 97% respectively. Regarding occlusion complexity there were no statistical significant differences in primary patency rates (TASC B vs. C vs. D: p = 0.19). There were no statistically significant differences in primary patency rates between patients in different clinical stages, as well as between the type of stents, and location of the occlusion.ConclusionIn our study, endovascular treatment for iliac artery occlusions proved to be a safe and efficient approach with excellent primary and secondary patency rates regardless of the complexity of occlusions defined by TASC II classification. This study is aligned with the notion that in well selected patients, endovascular therapy can be the treatment of choice even in complex iliac lesions if performed by experienced endovascular interventionists in high volume centers.

Primary Patency Rate of Arteriovenous Fistula Created for Hemodialysis Patients: The Indonesian Experience

IntroductionClinical practice guidelines endorse the arteriovenous fistula as the preferred form of vascular access. Concerns have been raised regarding its high risk of primary failure. Its estimated primary patency rate varies in the literature. Since most of the current data are from Western countries and information from the developing countries is scarce, we aim to evaluate the primary patency rate of arteriovenous fistula created for hemodialysis patients in our hospital. MethodologyWe analyzed data from all patients undergoing the creation of arteriovenous fistula for hemodialysis at the PGI Hospital Cikini in Jakarta, Indonesia, from January to December 2015. Information needed was retrieved from the medical records. Actuarial patency rate was created by the Kaplan-Meier product-limit method. Differences between curves were compared by means of a log-rank test. ResultsA total of 253 arteriovenous fistula in the upper arm were created in patients requiring hemodialysis. The overall 6-, 12-, and 18-month primary patency rates of arteriovenous fistula created for hemodialysis patients were 88%, 85%, and 79%, respectively. There was a difference in primary patency rate of arteriovenous fistula by gender. The 6- and 12-month primary patency rates of arteriovenous fistula created for male hemodialysis patients were 92% and 89%; the rates for female patients were 81% and 78%, respectively (P = .027). ConclusionsCareful preoperative patient assessment, optimal surgical techniques, and adequate postoperative care play an important role for the favorable outcome. The primary patency rate in male hemodialysis patients was significantly higher than in female patients.

Chronic Nonatherosclerotic Occlusive Popliteal Artery Disease

The outcomes of revascularization of nonatherosclerotic occlusive popliteal artery disease are unknown. Therefore, the objective of this study was to analyze the outcomes of recanalization of nonatherosclerotic occlusive popliteal artery disease, the results of which would be useful in creating surgical strategies for such cases. From January 2000 to December 2015, a total of 22 patients with nonatherosclerotic occlusive popliteal artery disease underwent open surgical repair. We retrospectively analyzed the data of these patients. Thrombectomy with angioplasty on the occluded popliteal artery, graft interposition, and bypass surgery were conducted for revascularization of the affected region. We analyzed the overall primary patency rate, type of graft, and surgical approach. Furthermore, we compared the primary patency rate after surgical treatment. Of 22 patients, 3 (13.6%) had cystic adventitial disease, 16 (72.7%) had popliteal artery entrapment syndrome, and 3 (13.6%) were diagnosed as having thromboangiitis obliterans. Five patients (22.7%) underwent thrombectomy with patch angioplasty, 8 (36.3%) underwent bypass surgery, and 9 (40.9%) underwent graft interposition of the popliteal artery. All graft interpositions and thrombectomies with patch angioplasty were performed through a posterior approach, whereas all bypass surgeries were performed through a medial approach except in 1 case. The mean follow-up period was 54.95±42.99months. The overall primary patency rate at 1, 3, and 10years was 100%, 86.9%, and 69.5%, respectively. In the bypass group, the primary patency rate at 1, 3, and 10years was 100%, 66.7%, and 44.4%, respectively. In the other groups, the primary patency rate was 100% during the follow-up period. The difference in primary patency rate was statistically significant (P≤0.05). The result of surgical treatment for nonatherosclerotic occlusive popliteal artery disease was better than that of atherosclerotic popliteal artery disease. Direct popliteal artery reconstruction, such as graft interposition or thrombectomy with patch angioplasty, showed better short- and long-term patency than did bypass surgery.

The Role of Common Femoral Artery Endarterectomy in the Endovascular Era

The purpose of this study was to review our experiences treating peripheral artery disease (PAD) by common femoral artery endarterectomy (CFE) with and without endovascular therapy (EVT), and to describe the role of CFE in the endovascular era. We retrospectively reviewed a contemporary series of 38 limbs from January 2010 to September 2014. Clinical outcomes of primary patency, assisted primary patency, limb salvage, and survival were analyzed with the Kaplan-Meier method. Multivariable perioperative predictors of primary patency were identified using the stepwise Cox proportional hazards regression model. Hemodynamic success was achieved in 36 of the 38 limbs (95%). The mean ankle brachial pressure index improved significantly, rising from 0.56 ± 0.04 preoperatively to 0.89 ± 0.04 postoperatively (P = 0.0001). Overall primary and assisted primary patency rates, respectively, were 90% and 100% at 12 months and 85% and 94% at 24 months. There was no significant difference in primary patency rate between isolated CFE and hybrid CFE plus EVT. Both limb salvage and survival rates were 97% at 12 months and 97% at 24 months. Multivariate Cox regression analysis revealed that no clinical or perioperative risk factors were predictive of decreased primary patency. CFE is a safe, effective, and durable procedure for common femoral artery disease, and hybrid CFE plus EVT can be a valid alternative to open surgical bypass for multilevel occlusive artery disease. These observations stress that CFE plays a vital role in the management of PAD even in the endovascular era.

Cutting balloon angioplasty versus conventional balloon angioplasty in hemodialysis access stenoses: Multicenter prospective randomized comparison of primary patency rates.

Purpose:  To compare primary patency rates of cutting balloon percutaneous transluminal angioplasty and conventional balloon percutaneous transluminal angioplasty in the treatment of different types of hemodialysis access stenosis. Patients  and  methods:   58  patients  with  different  types  of hemodialysis  access  stenosis in  whom  PTA  was indicated   were prospectively,  randomized  to have  either  conventional balloon percutaneous transluminal  angioplasty or cutting balloon percutaneous transluminal angioplasty   The  study  was  performed  at  3 medical  centers  in  Saudi  Arabia  {Al-Moosa Specialized  hospital  Al-Ahsaa,  Tabuk University,  & Saudi  German  Hospital  Riyadh).  The primary patency rates of conventional PTA group & cutting balloon PTA group were compared The patients were followed up for 15 months. Primary patency rates  for lesions were calculated with the Kaplan-Meier method according to the type of stenosis.compared  the two groups by using the log-rank test to determine statistical significance. Results:  In the cutting PTA group, 26 patients with 29 stenoses achieved clinical success. In the conventional PTA group, 25 patients with 30 stenoses achieved clinical success. In patients with graft-to vein anastomotic  stenosis, the primary patency rate was significantly higher for cutting PTA than for conventional PTA (P = .037).In patients with autogenous venous stenosis, intragraft  stenosis and arterial anastomotic  stenosis, no significant difference in the primary patency rate was noted between groups (P = .360, .371 & .921 respectively). Conclusion: Primary patency rates are significantly higher for cutting PTA in the treatment of graft-to-vein  anastomotic  stenosis, however, no significant differences in primary patency rates  exist  between  these  PTAs in  the  treatment  of autogenous  venous stenosis, intragraft stenosis, or arterial anastomotic stenosis.

Interposition vein cuff for infragenicular prosthetic bypass graft

The use of prosthetic grafts such as polytetrafluorethylene (PTFE) or Dacron to bypass occluded arteries in the lower leg is an accepted practice in the absence of suitable autologous vein. The aim is limb salvage or functional improvement in critical limb ischaemia, but patency rates for below knee prosthetic bypasses are low. Creating a vein cuff at the distal anastomosis is thought to improve outcomes. Other techniques including the use of pre-cuffed synthetic grafts, spliced segments of vein and the creation of an arterio-venous fistula (AVF) are also used to improve patency. To compare the beneficial effects of using vein cuffed prosthetic grafts for below knee bypass in critical limb ischaemia with other types of reconstruction. The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2012) and CENTRAL (2012, Issue 5) for publications comparing prosthetic infragenicular bypass using vein cuffs with other bypass techniques. Randomised controlled trials comparing interposition vein cuff prosthetic graft with autologous vein graft and non-cuffed prosthetic graft for infragenicular bypass in patients with critical limb ischaemia were included. Trials comparing vein cuff prosthetic grafts with or without AVF and vein cuff prosthetic grafts with pre-cuffed prosthetic grafts were also included. The trials were selected and assessed independently by two review authors. Six trials with a combined total of 885 patients were included in this review. Only studies using prosthetic PTFE grafts were identified.Two trials compared PTFE graft with or without a vein cuff. In one underpowered trial for below knee bypass the cumulative primary patency rate was statistically significantly higher in the vein cuff group (80.3% versus 65.3% at 12 months and 51.8% versus 29.1% at 24 months, P = 0.03). There was no statistically significant difference in secondary patency (82.9% versus 72.5% and 58.6% versus 34.9%, P = 0.14) and limb salvage rates (86.3% versus 71.8% and 82.6% versus 62.2%, P = 0.08) at 12 and 24 months respectively. The other trial showed no statistically significant difference between the groups at three years in the below knee femoro-popliteal bypasses (primary patency rate 26% (95% confidence interval (CI) 18 to 38) and 43% (95% CI 33 to 58), secondary patency rate 32% (95% CI 23 to 44) and 42% (95% CI 31 to 56) and limb salvage rate 64% (95% CI 54 to 75) and 61% (95% CI 50 to 74) in the collar and no collar groups respectively). In the femoro-distal bypass group, the differences in primary patency, secondary patency and limb salvage rates were also not statistically significant at three years (primary patency rate 20% (95% CI 11 to 38) and 17% (95% CI 9 to 33), secondary patency rate 22% (95% CI 12 to 39) and 20% (95% CI 11 to 35) and limb salvage rate 59% (95% CI 46 to 76) and 44% (95% CI 32 to 61) in the collar and no collar groups respectively).One trial compared pre-cuffed PTFE grafts with vein cuffed grafts. There was no statistically significant difference in primary patency rate (62% pre-cuffed PTFE versus 52% vein cuff PTFE and 49% versus 44%, P = 0.53), secondary patency rate (66% pre-cuffed PTFE versus 53% vein cuff PTFE and 55% versus 50%, P = 0.30) or limb salvage rate (75% pre-cuffed PTFE versus 72% vein cuff PTFE and 62% versus 65%, P = 0.88) at 12 and 24 months respectively.One trial compared spliced vein grafts with vein cuffed PTFE grafts. At 24 months, the secondary patency rate was statistically significantly higher in the spliced vein group (86% in the spliced vein and 52% in the vein cuff group, P < 0.05). There was no statistical significant difference in primary patency rate (44% versus 50%, P > 0.05) and limb salvage rate (94% versus 85%, P > 0.05).Two trials compared vein cuff PTFE grafts with and without AVF. There was no statistical significant difference at 24 months in primary patency rate (29% versus 36%, P = 0.77; 32% versus 28%, P = 0.2), secondary patency rate (40% versus 40%, P = 0.89; 28% versus 24%, P = 0.2) and limb salvage rate (65% versus 70%, P = 0.97; 62% versus 71%, P = 0.3). There is evidence that a vein cuff at the distal anastomosis site improves primary graft patency rates for below knee PTFE graft, but this does not reduce the risk of limb loss. Pre-cuffed PTFE grafts have comparable patency and limb salvage rates to vein cuff PTFE grafts. The use of spliced veins improved secondary patency but this did not translate into improved limb salvage. The use of an AVF alone showed no added benefits. Evidence for a beneficial effect of vein cuffed PTFE grafts is weak and based on underpowered trials. A large study with a specific focus on below knee vein cuff prosthetic grafts, including PTFE, is required.

Impact of Race on Infrainguinal Angioplasty and Stenting

Over the last decade, catheter-based interventions on lower extremity arteries have been used with increasing frequency. However, the effect of racial background on the outcome of lower extremity endovascular interventions for peripheral arterial disease is unknown. The purpose of this study was to determine the effect of patients' race on the durability of angioplasty and stenting performed on the superficial femoral and popliteal arteries. The records of all patients undergoing percutaneous intervention on the lower extremity arteries during a 14-year period were reviewed. During a 44-month period (2003-2007), all patients underwent primary stenting as part of a prospective study protocol. Indication for intervention, TransAtlantic InterSociety Consensus II classification, runoff anatomy, site of intervention, and the placement of stents were noted. Results were analyzed by race. Kaplan-Meier life survival curves were plotted and differences between groups tested by log-rank method. Cox proportional hazards regression model was used to perform the multivariate analysis. Between 1994 and 2007, a total of 374 percutaneous interventions were performed on the superficial femoral and popliteal arteries in 280 patients. Of these, 182 procedures were angioplasties and 192 included both angioplasty and stenting. The study group consisted of 60% Caucasians, 23% Hispanics, 12% African Americans, and 5% Asians. No difference in primary patency rates was noted between individuals belonging to different races. However, in those undergoing angioplasty alone, Caucasians had the highest rate of failure, followed by Hispanics, African Americans, and then Asians (p < 0.002). No difference in patency rates between races was seen in patients undergoing angioplasty with stenting. For the entire group, dyslipidemia, TransAtlantic InterSociety Consensus II C and D lesions, and angioplasty without stenting negatively affected primary patency. Race does not appear to influence the durability of catheter-based procedures performed on the superficial femoral and popliteal arteries. However, in patients who underwent angioplasty alone, it was noted that Caucasians had the highest rates of failure and Asians the lowest. However, this difference was no longer apparent when stents were used.

Two-stage brachial-basilic transposition fistula provides superior patency rates for dialysis access in a safety-net population

Guidelines of the National Kidney Foundation recommending aggressive pursuit of autogenous fistulae for dialysis access in lieu of prosthetic arteriovenous grafts have stimulated a renewed interest in transposed brachial-basilic fistulae as an alternative technique for upper arm access in patients who may not be candidates for a lower arm radial-cephalic or forearm brachial-cephalic fistula. We hypothesized that in our safety-net population, where radial-cephalic and brachial-cephalic often are not possible, brachial-basilic would provide patency rates superior to arteriovenous grafts and equivalent to radial-cephalic and brachial-cephalic fistulae. We analyzed retrospectively our most recent 2.5-year experience with dialysis access procedures at our metropolitan safety-net hospital. Procedures were grouped as follows: radial-cephalic, brachial-cephalic, brachial-basilic, and arteriovenous grafts. The access outcomes measured were primary failure, time to use, need for intervention, and primary as well as secondary patency. Differences in age, sex, race, renal function (Modification of Diet in Renal Disease), baseline diagnoses (diabetes mellitus, hypertension, coronary artery disease, and peripheral vascular disease), as well as the number of previous accesses, were adjusted in the analysis. Logistic regression was used to identify independent predictors of primary failure, and Kaplan-Meier plots assessed differences in primary patency rates. A log of the time variables was used to approximate normal distribution. In all, 193 patients were included in this study as follows: radial-cephalic, 75 (39%) patients; brachial-cephalic, 35 (18%) patients; brachial-basilic, 33 (17%) patients; and arteriovenous grafts, 50 (26%) patients. Primary patency means differed marginally between groups (P = .08), and when grafts were excluded from the analysis, no difference was found between primary patency in all autogenous fistula techniques (P = .88). Kaplan-Meier plots showed that when analyzing the first 35 weeks, a significantly lower primary patency among graft recipients early after the procedure was noted, and a higher performance of BB after 20 weeks was noted (log-rank P = .05, Wilcoxon P = .004). Furthermore, secondary patency did not vary significantly between groups (P = .62). Radial-cephalic were more likely to fail primarily when compared with the other access groups (P = .03), and in a univariate analysis, underlying hypertension was associated with a lower risk of primary failure (P = .01) compared with other diagnoses. A logistic regression stepwise selection showed that the underlying diagnoses of peripheral vascular disease, diabetes mellitus, or coronary artery disease were associated with a greater risk of primary failure compared with those with HTN (P = .001; oddsratio, 4.05; 95% confidence interval, 1.71-9.59), as well as the presence of a previously failed access (P= .04; odds ratio, 2.39; 95% confidence interval, 1.08-5.67). In a safety-net population, our results suggest that 2-stage brachial-basilic transposition fistulae provide patency rates equivalent to brachial-cephalic and radial-cephalic fistulae and superior to grafts. Although 2 procedures are required, brachial-basilic fistulae provide a reliable access and should be considered the next choice when radial-cephalic and/or brachial-cephalic are not possible.

Primary Patency with Cutting and Conventional Balloon Angioplasty for Different Types of Hemodialysis Access Stenosis

To compare primary patency rates of cutting balloon percutaneous transluminal angioplasty (PTA) (hereafter, cutting PTA) and conventional balloon PTA (hereafter, conventional PTA) in the treatment of different types of hemodialysis access stenosis. The institutional review board approved this study. Written informed consent was obtained for the prospective component of this study and waived for the retrospective component. Patients in whom treatment with cutting PTA alone or conventional PTA alone was clinically successful formed the two study groups. Primary patency for the lesion was defined as uninterrupted patency of the treated site after balloon PTA. A site was no longer considered patent when the patient underwent treatment for hemodialysis access failure due to restenosis of the treated site. Primary patency rates for lesions were calculated with the Kaplan-Meier method according to the type of stenosis. We compared the two groups by using the log-rank test to determine statistical significance. In the cutting PTA group, 62 patients with 77 stenoses (32 men, 30 women; mean age, 65.5 years +/- 10.1 [standard deviation]) achieved clinical success. In the conventional PTA group, 52 patients with 68 stenoses (23 men, 29 women; mean age, 61.9 years +/- 10.2) achieved clinical success. In patients with autogenous venous stenosis, no significant difference in the primary patency rate was noted between groups (P = .369). In patients with graft-to-vein anastomotic stenosis, the primary patency rate was significantly higher for cutting PTA than for conventional PTA (P = .39). In patients with intragraft stenosis, no significant difference in the primary patency rate was noted between groups (P = .379). In patients with in-stent restenosis, no significant difference in the primary patency rate was noted between groups (P = .923). Primary patency rates are significantly higher for cutting PTA in the treatment of graft-to-vein anastomotic stenosis; however, no significant differences in primary patency rates exist between these PTAs in the treatment of autogenous venous stenosis, intragraft stenosis, or in-stent restenosis.

Effects of Omega-3 Fatty Acid Supplementation on Vascular Access Thrombosis in Polytetrafluorethylene Grafts

The purpose of this study was to investigate the effects of orally administered over-the-counter omega-3 (n-3) fatty acid supplements on primary patency of polytetrafluoroethylene (PTFE) grafts. This study was conducted with a triple-blind, permuted-block, randomized, placebo-controlled experimental design. Dialysis clinics with patients who, in accordance with physician diagnosis, needed a new PTFE graft. Patients on long-term hemodialysis with newly placed PTFE grafts who were unable to receive a native arteriovenous fistula. Patients were followed prospectively for 8 months after they had been placed into an n-3 fatty acid or control group and were monitored for primary patency. Primary patency of the PTFE graft. The n-3 fatty acid group had a mean PTFE graft primary patency rate of 254.2 days (SEM = 51.8), and the control group had a mean PTFE graft primary patency rate of 254.1 days (SEM = 34.6), revealing no significant difference in survival time between groups. No significant differences in primary patency rates were noted in the experimental and control groups.

Efficacy of percutaneous fibrin sheath stripping in restoring patency of tunneled hemodialysis catheters.

Our objective was to determine the effectiveness of percutaneous fibrin sheath stripping as a method of restoring function to failing tunneled hemodialysis catheters. A total of 131 percutaneous fibrin sheath stripping procedures were performed on 100 failing tunneled hemodialysis catheters in 91 patients. Only the initial stripping procedure of the first catheter inserted in each patient was included for analysis. Patients were excluded if an additional cause of catheter failure was noted at the time of percutaneous fibrin stripping. Failure of the hemodialysis catheter was defined as inability to sustain an average blood flow rate of 250 ml/min or more in a hemodialysis session. Patients were followed up until the time of catheter failure, catheter removal, or a second stripping. Poststripping primary patency and complication rates were determined. The technical success of the procedure was 95.6%. Median follow-up was 16 weeks (range, 0-128 weeks). The overall median duration of primary patency after the first stripping was 89 days (3 months). No statistically significant difference in primary patency rates was seen between patients who underwent fibrin sheath demonstration by contrast injection and those who did not (p = .71). Female patients were statistically more likely to have catheter failure after catheter stripping than were male patients (p = .02). The route of catheter insertion did not significantly influence poststripping patency rates. No complications were associated with the procedure. Percutaneous fibrin sheath stripping is a safe, effective method of restoring patency to failing hemodialysis catheters when the failure is due to fibrin sheath formation and other causes are excluded.

Superior vena cava obstruction: Clinical syndrome, etiology, and treatment

To retrospectively evaluate the technical and clinical outcomes of superior vena cava (SVC) stent placement through upper-limb venous access in malignant SVC syndrome (SVCS) and compare the efficacy of different nitinol stent types.Between 2006 and 2018, 156 patients (132 male; mean age, 62 y; age range, 33–81 y) underwent SVC stent placement for malignant obstructions through upper-limb venous access with 1 of 3 types of nitinol stent: 1 venous-dedicated (Sinus-XL stent) and 2 non–venous-dedicated (E-Luminexx Vascular Stent and Protégé GPS). Cases of common femoral vein access or non-nitinol stents were excluded from further analysis. The mean duration of follow-up was 8 mo.Technical success was achieved in 99.3% of cases. One patient died during the procedure as a result of cardiac tamponade. Balloon predilation was performed in 10 patients and postdilation in 126. Mean procedural time was 34.4 min (range, 18–80 min). Overall survival rates were 92.3%, 57.3%, and 26.8%, and overall primary patency rates were 94.5%, 84.8% and 79.6%, at 1, 6, and 12 mo, respectively. There were no statistically significant differences in primary patency rates between venous- and non–venous-dedicated stents or among different Stanford SVCS grading groups (P > .05).SVC stent placement through an upper-limb approach is a safe, fast, and effective technique. There is no evident benefit of venous-dedicated vs non–venous-dedicated stents in the treatment of malignant SVCS.